Recently, Clindata^® has submitted two international patents. A total of Eleven invention patents related to new drug research and development have been applied for, which were accepted by the State Intellectual Property Office of China and simultaneously applied for international patents. A number of patents are used to protect the innovative content of Clindata^® in the research and development of new drugs. The content involved in these patents is the first of its kind in the world. At the same time, it is applying for an international patent.

In less than a year, Clindata^® has obtained 27 software copyrights, involving the existing technological gaps in the development of innovative drugs, solving the problem of "stuck neck" in the development of new drugs.

These patent applications demonstrate the strong innovation capabilities of the Clindata^® team and are the first in a series of patent applications that are being prepared by the Clindata^®. Under the guidance of the wisdom of interdisciplinary experts from around the world, Clindata^® is advancing dozens of projects related to "stuck neck" problems in the process of new drug research and development, and will also apply for Chinese and international patents one after another.

Clindata^® is the first innovative CRO in China that focuses on innovative strategies and design of innovative drugs for major diseases such as cancer. Clindata^® has set a vision for 2040: to help 200 innovative drugs to be launched; to increase the success rate of new drug development in major diseases such as tumors from 9% to 20%; to shorten the traditional 5-10 years of clinical trials To 3-4 years; cut existing R&D costs in half.